Evidence map›Paper›PMID 41318372›Full record

ArticleBMC gastroenterology2025

Serum REG1A protein is a biomarker for diagnosis and progression prediction of pancreatitis.

Qi-Wen Wang, De-Jian Bian, Zhi-Qin Xie, Xin Geng, Hao-Rui Zheng, Bo-Wen Li, Ying-Gang Xu, Wen-Bin Zou, Zhuan Liao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qi-Wen Wang *Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
De-Jian Bian *Department of Emergency, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Zhi-Qin Xie *Department of Hepatobiliary and Pancreatic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412007, China.
Xin Geng *National Center for Liver Cancer, Naval Medical University, Shanghai, 200433, China.
Hao-Rui ZhengDepartment of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Bo-Wen LiDepartment of Hepatobiliary and Pancreatic Surgery, Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412007, China.
Ying-Gang XuDepartment of Emergency, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Wen-Bin ZouDepartment of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. dr.wenbinzou@hotmail.com.
Zhuan LiaoDepartment of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. zhuanleo@126.com.

Funding

the National Natural Science Foundation of China 82120108006
6 · The paper itself

Abstract

backgroundSerum regenerating islet-derived protein 1 alpha (REG1A), a protein associated with pancreatic inflammation, is emerging as a potential biomarker for pancreatitis. This case-control study aimed to evaluate the diagnostic and prognostic value of REG1A in patients with acute pancreatitis (AP) and chronic pancreatitis (CP).

methodsA total of 349 participants were recruited prospectively from two centers, including healthy controls (n = 70), AP (n = 169), and CP (n = 110). Serum REG1A levels were measured, and diagnostic performance was assessed. The correlations of REG1A with disease progression were evaluated using univariate and multivariate logistic regression analyses.

resultsSerum REG1A levels were significantly elevated in both AP and CP patients compared to controls. REG1A demonstrated high accuracy for distinguishing AP and CP from controls (Area under the curve (AUC): 0.914 and 0.875, respectively). In AP, REG1A levels increased with disease severity (P < 0.001) and demonstrated moderate diagnostic performance for severe AP with an AUC of 0.750 (95% CI: 0.671-0.828). REG1A outperformed C-reactive protein (CRP) and procalcitonin (PCT) as an independent predictor of severe AP (OR = 1.058 per 10 ng/ml; 95% CI, 1.022-1.094, P = 0.001). In CP, REG1A levels correlated positively with disease stages (r = 0.309, P < 0.001) and remained an independent predictor of pancreatic insufficiency (OR = 1.089 per 10 ng/ml, 95% CI, 1.010-1.174, P = 0.027). REG1A had a moderate diagnostic accuracy for distinguishing CP patients with pancreatic insufficiency from those without with an AUC of 0.700 (95% CI: 0.600-0.800).

conclusionsSerum REG1A is a promising biomarker for diagnosing pancreatitis, and predicting both AP severity and CP progression. These findings underscore the potential role of REG1A in the diagnosis and management of pancreatitis.

Indexed as

LithostathinePancreatitisPancreatitis, ChronicAcute DiseaseAdultAgedBiomarkersCase-Control StudiesC-Reactive ProteinDisease ProgressionFemaleHumansMaleMiddle AgedPancreatitis-Associated ProteinsPredictive Value of TestsBiomarkersC-Reactive ProteinLithostathinePancreatitis-Associated ProteinsProcalcitoninREG1A protein, humanAcute pancreatitisBiomarkerChronic pancreatitisDiagnostic accuracyDisease severityREG1A

Identifiers

PMID41318372
PMCPMC12771855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.